title: Impaired systolic blood pressure response to dobutamine stress testing: a marker of more severe functional abnormalities in patients with myocardial infarction.
abstract: Dobutamine-induced hypotension has been disregarded as a marker of more severe functional abnormalities in patients with suspected coronary artery disease. However, its functional significance in patients with myocardial infarction has not been studied. The aim of this study was to define the predictors of systolic blood pressure (SBP) response to dobutamine in patients with previous myocardial infarction. Dobutamine stress (up to 40 microg/kg per minute) echocardiography was performed in 326 patients with prior myocardial infarction referred for evaluation of myocardial ischemia. A 16-segment, four-grade score model was used to assess left ventricular function. Wall motion score index was derived by summation of wall motion score divided by 16. SBP and heart rate increased from rest to peak dobutamine stress (127 +/- 22 vs 134 +/- 27 mm Hg and 72 +/- 14 vs 122 +/- 24 bpm, p < 0.00001 in both). An increase of SBP > or = 30 mm Hg occurred in 50 patients (15%). By multivariate analysis, independent predictors of failure of SBP increase were higher peak wall motion score index (p < 0.001), higher resting SBP (p < 0.01), and medication with calcium channel blockers (p < 0.05). SBP drop > or = 20 mm Hg occurred in 54 patients (17%). Independent predictors of SBP drop were higher resting wall motion score index (p < 0.001), higher resting SBP (p < 0.0001), and older age (p < 0.05). In patients with myocardial infarction, left ventricular function and baseline systolic blood pressure are powerful predictors of SBP response to dobutamine stress testing.
authors.affiliation: Thoraxcenter, Rotterdam, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Elhendy
authors.forename: R T
authors.initials: RT
authors.lastname: van Domburg
authors.forename: P R
authors.initials: PR
authors.lastname: Nierop
authors.forename: M L
authors.initials: ML
authors.lastname: Geleijnse
authors.forename: J J
authors.initials: JJ
authors.lastname: Bax
authors.forename: J D
authors.initials: JD
authors.lastname: Kasprzak
authors.forename: A F
authors.initials: AF
authors.lastname: Liqui-Lung
authors.forename: M M
authors.initials: MM
authors.lastname: Ibrahim
authors.forename: J R
authors.initials: JR
authors.lastname: Roelandt
mesh_terms: D000318:Adrenergic beta-Agonists; D001794:Blood Pressure / Q000187:drug effects*; D017023:Coronary Angiography; D004280:Dobutamine; D004452:Echocardiography / Q000379:methods*; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000503:physiopathology*; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D000318:Adrenergic beta-Agonists; D004280:Dobutamine